Amarin Corp Plc (AMRN)

[TortLaw]

Pure EPA Vascepa(R) Now Available in New, Smaller Half-Gram Capsule Size

Amarin Expands Vascepa Franchise with First-and-Only 0.5-gram Prescription Omega-3 Option for Healthcare Providers Treating Patients Who Prefer a Smaller Capsule

BEDMINSTER, N.J. and DUBLIN, Ireland , Oct. 25, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today the introduction of a smaller 0.5-gram capsule size for Vascepa® (icosapent ethyl) available now in retail pharmacies nationwide. The smaller capsule is in addition to the original and currently available 1-gram size Vascepa capsule.
Vascepa 0.5g Capsules
Vascepa 0.5g Capsules


A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3f18752c-0265-452a-b8e2-1920b8267071

"Amarin is dedicated to listening to patients and healthcare providers in an effort to deliver solutions that help make it easier for patients to take their doctor prescribed medication," said Aaron Berg , senior vice president of marketing and sales of Amarin. "We are pleased to now offer the first and only half-gram prescription omega-3 alternative for the subset of patients who prefer a smaller capsule."

The FDA -approved dosing for Vascepa continues to be four grams per day, taken as two grams twice daily, with food. Based on market research with healthcare providers, Amarin believes that the majority of patients taking Vascepa will continue to be prescribed the 1-gram size Vascepa capsule.